Credit Suisse Ag Vertex Pharmaceuticals Inc Call Options Transaction History

Credit Suisse Ag

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $672,638 - $849,110	3,800 Added 100.0%	7,600 $1.67 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $235,806 - $263,887	-1,300 Reduced 25.49%	3,800 $689,000
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $149,992 - $176,880	800 Added 18.6%	5,100 $1.03 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $8.9 Million - $10.4 Million	-43,000 Reduced 90.91%	4,300 $924,000
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $2.05 Million - $2.73 Million	9,900 Added 26.47%	47,300 $11.2 Million

Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $178,955 - $212,170	700 Added 1.91%	37,400 $10.2 Million
Q2 2020 Aug 12, 2020	BUY	$225.48 - $295.8 $3.31 Million - $4.35 Million	14,700 Added 66.82%	36,700 $10.7 Million
Q1 2020 May 13, 2020	SELL	$199.77 - $247.81 $219,747 - $272,591	-1,100 Reduced 4.76%	22,000 $5.24 Million
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $116,697 - $156,737	700 Added 3.13%	23,100 $5.06 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $265,968 - $299,344	1,600 Added 7.69%	22,400 $3.8 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $14.8 Million - $17.1 Million	-89,700 Reduced 81.18%	20,800 $3.81 Million
Q1 2019 May 14, 2019	SELL	$163.73 - $194.7 $35.6 Million - $42.3 Million	-217,300 Reduced 66.29%	110,500 $20.3 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $46.9 Million - $59.4 Million	308,800 Added 1625.26%	327,800 $54.3 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $2.77 Million - $3.23 Million	19,000 New	19,000 $3.23 Million

1,624

222M

1.35M

1.49M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $121B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.